Abstract
Multiple agents have been tried in patients with refractory immune thrombocytopenic purpura (ITP); however, none of these stands as a clear first choice. We administered rituximab, 375 mg/m2 weekly x 4, to four patients with refractory ITP. With a median follow-up of 7 months, one patient has achieved a complete response, proving the possible efficacy of such a therapeutic modality in this context.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Autoimmune Diseases / therapy*
-
Drug Evaluation
-
Female
-
Follow-Up Studies
-
Humans
-
Immunotherapy*
-
Middle Aged
-
Purpura, Thrombocytopenic, Idiopathic / therapy*
-
Remission Induction
-
Rituximab
-
Salvage Therapy
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab